At the European Health Forum in Gastein, Austria, Spain's Health Secretary Javier Padilla Bernáldez urged the European Union to adopt a coordinated stance against US attempts to set drug prices via bilateral agreements, warning that such deals could fragment Europe's market power and delay access to new medicines.

Key Takeaway

Country: Spain (Secretary of Health Javier Padilla Bernáldez)
Venue: Gastein, Austria
Date: 1 Oct 2026

Background

Europe's pharmaceutical pricing landscape has been shaped by divergent national strategies. France recently secured a predictable pricing framework, while Germany is engaged in talks with US authorities following a Section 301 trade investigation. The European Commission has requested an impact assessment of a potential Most‑Favored‑Nation (MFN) clause advocated by the Trump administration, though concrete outcomes remain uncertain.

Development

During the forum, Padilla Bernáldez emphasized that Europe's strength lies in its unified market and universal health coverage. He cautioned that bilateral pacts with the United States could fragment this advantage and stall the arrival of innovative drugs. The EU is considering applying an MFN mechanism to align medication prices in the US with those in Europe, but implementation will depend on future political decisions.

Outlook

It is likely that the EU will continue to champion collective bargaining to safeguard access to cutting‑edge therapies and curb price inflation. The upcoming vote in the Committee on the Environment on the Biotech Act will be pivotal; legislation that limits patent extensions could reshape pricing dynamics and enhance competitiveness across the bloc.